131I-MIBG (iobenguane I-131) therapy
High-dose radioactive MIBG delivers radiation from inside neuroblastoma cells that take up noradrenaline; used for relapsed disease and tested in upfront therapy.
Response rate ~30-40% in relapsed/refractory MIBG-avid neuroblastoma (NANT, COG studies), with myelosuppression requiring stem-cell support at ≥12 mCi/kg. COG ANBL1531 randomised 131I-MIBG added to induction (primary results pending 2026). Commercial Azedra (for pheochromocytoma) was discontinued in 2024, leaving compounding and academic supply.
- Route
- IV
- Schedule
- 12-18 mCi/kg single or tandem doses with autologous stem-cell support; thyroid blockade with potassium iodide
- Monitoring
- Radiation isolation, counts, thyroid function, secondary malignancy
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"131I-MIBG iobenguane I-131 therapy" OR ABSTRACT:"131I-MIBG iobenguane I-131 therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 131I-MIBG (iobenguane I-131) therapy, not a curated reading list.